Dompé U.S. Inc. Settlement: Regulatory Scrutiny and Compliance
Dompé U.S. Inc., a subsidiary of Dompé farmaceutici S.p.A., reached a $32 million settlement with the U.S. Department of Justice over allegations of violating the Anti-Kickback Statute and the False Claims Act.
The settlement relates to Dompé's involvement in providing financial support through patient assistance foundations to cover Medicare co-pays for its drug, Oxervate. These actions, conducted between 2018 and 2021, were aimed at encouraging the purchase of Oxervate, raising regulatory concerns about the relationship between drug manufacturers and co-pay assistance charities. The pharmaceutical industry is under intensified regulatory scrutiny, as demonstrated by related cases such as the $450 million settlement by Teva Pharmaceuticals in 2024 over its drug Copaxone and ongoing litigation involving Regeneron in Massachusetts.
Industry Implications and Regulatory Scrutiny
The Dompé U.S. case is part of a broader trend of regulatory actions targeting improper interactions between pharmaceutical companies and co-pay assistance foundations. Such foundations are intended to ease medication costs for patients, yet allegations of manipulation by manufacturers highlight potential conflicts and raise compliance issues. These settlements signal to insurance professionals and compliance teams the critical importance of rigorous oversight and adherence to regulatory frameworks to avoid legal and financial repercussions.
Voluntary Disclosure and Compliance
Interestingly, Dompé farmaceutici's proactive disclosure of its conduct to the U.S. Attorney's Office aligns with new directives in the Justice Manual encouraging voluntary reporting. By sharing data from patient assistance foundations and a specialty pharmacy with internal teams, Dompé U.S. engaged in practices that have now been addressed through this settlement. For compliance professionals, this emphasizes the significance of voluntary disclosure as a strategic move to potentially mitigate enforcement actions.
Comparative Case Settlements
| Company | Allegation | Settlement Amount |
|---|---|---|
| Teva Pharmaceuticals | Co-pay assistance misuse for Copaxone |
$450 million |
| Dompé U.S. Inc. | Anti-Kickback and False Claims involving Oxervate |
$32 million |
Broader DOJ Actions
Further illustrating the DOJ's active stance, Abbott Laboratories agreed to pay $385 million to resolve allegations of false claims related to non-compliant production of infant formula and nutritional products. Additionally, Accenture settled for $25 million over discriminatory practices in federal contracts. Both cases underscore the DOJ’s commitment to enforcing compliance across diverse sectors, putting insurance and corporate compliance teams on notice regarding the strict enforcement of regulatory standards and practices.
Lastly, Global Wound Care Medical Group’s bankruptcy-linked $525 million settlement highlights the severe consequences of fraudulent claims to federal healthcare programs. This development serves as a crucial reminder for insurance carriers and claims professionals about the vital role of transparency and due diligence in maintaining operational integrity and compliance.